241 related articles for article (PubMed ID: 37904659)
1. Drug-Eluting Bead Transarterial Chemoembolization Versus Radiofrequency Ablation as an Initial Treatment of Single Small (≤ 3 cm) Hepatocellular Carcinoma.
Lee S; Jeong YY; Lee BC; Shin SS; Heo SH; Kim HO; Park C; Jeong WG
J Korean Med Sci; 2023 Oct; 38(42):e362. PubMed ID: 37904659
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients.
Zhu D; Yuan D; Wang Z; Chen S
Medicine (Baltimore); 2019 Jun; 98(26):e15682. PubMed ID: 31261491
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of combined transarterial chemoembolization and radiofrequency ablation versus RFA monotherapy for single hepatocellular carcinoma ≤3 cm: emphasis on local tumor progression.
Cao S; Zou Y; Lyu T; Fan Z; Guan H; Song L; Tong X; Wang J
Int J Hyperthermia; 2022; 39(1):1-7. PubMed ID: 34937501
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation.
Wang X; Liang H; Lu Z
Minim Invasive Ther Allied Technol; 2020 Dec; 29(6):344-352. PubMed ID: 31375044
[No Abstract] [Full Text] [Related]
5. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
[TBL] [Abstract][Full Text] [Related]
6. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
[TBL] [Abstract][Full Text] [Related]
7. Drug-eluting bead transarterial chemoembolization (DEB-TACE) versus conventional transarterial chemoembolization (cTACE) in colorectal liver metastasis: Efficacy, safety, and prognostic factors.
Zhang H; Wu C; Chen M; Sun Y; Han J
J Cancer Res Ther; 2023 Dec; 19(6):1525-1532. PubMed ID: 38156918
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
[TBL] [Abstract][Full Text] [Related]
9. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
[TBL] [Abstract][Full Text] [Related]
10. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients.
Li N; Chen J
Ir J Med Sci; 2022 Dec; 191(6):2611-2617. PubMed ID: 35083645
[TBL] [Abstract][Full Text] [Related]
12. Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival.
Lee DH; Lee JM; Kim PN; Jang YJ; Kang TW; Rhim H; Seo JW; Lee YJ
Eur Radiol; 2019 Sep; 29(9):5052-5062. PubMed ID: 30770968
[TBL] [Abstract][Full Text] [Related]
13. Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study.
Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Li C
Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101535. PubMed ID: 33121882
[TBL] [Abstract][Full Text] [Related]
14. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
15. Transarterial chemoembolization using drug-eluting bead compared with radiofrequency ablation for treatment of single small hepatocellular carcinoma: a pilot non-randomized trial.
Kim TH; Kim NH; Kim JD; Kim YN; Kim YJ; Kim EJ; Yoo KD; Ryu CH; Song HH; Kim H
J Liver Cancer; 2021 Sep; 21(2):146-154. PubMed ID: 37383084
[TBL] [Abstract][Full Text] [Related]
16. Combined transarterial chemoembolization and radiofrequency ablation for subphrenic versus nonsubphrenic hepatocellular carcinoma: a propensity score matched study.
Kim JG; Cho SK; Hyun D; Shin SW; Park KB; Park HS; Choo SW; Do YS; Woo SY; Baek SY
Abdom Radiol (NY); 2021 Dec; 46(12):5735-5745. PubMed ID: 34581928
[TBL] [Abstract][Full Text] [Related]
17. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.
Peng Z; Wei M; Chen S; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Kuang M
Eur Radiol; 2018 Aug; 28(8):3522-3531. PubMed ID: 29536241
[TBL] [Abstract][Full Text] [Related]
18. Early Stage Hepatocellular Carcinomas Not Feasible for Ultrasound-Guided Radiofrequency Ablation: Comparison of Transarterial Chemoembolization Alone and Combined Therapy with Transarterial Chemoembolization and Radiofrequency Ablation.
Hyun D; Cho SK; Shin SW; Park KB; Park HS; Choo SW; Do YS; Choo IW; Lee MW; Rhim H; Lim HK
Cardiovasc Intervent Radiol; 2016 Mar; 39(3):417-25. PubMed ID: 26246215
[TBL] [Abstract][Full Text] [Related]
19. Combined transarterial chemoembolization and radiofrequency ablation for small treatment-naïve hepatocellular carcinoma infeasible for ultrasound-guided radiofrequency ablation: long-term outcomes.
Hyun D; Cho SK; Shin SW; Park KB; Lee SY; Park HS; Do YS
Acta Radiol; 2018 Jul; 59(7):773-781. PubMed ID: 29034691
[TBL] [Abstract][Full Text] [Related]
20. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.
Bai XM; Cui M; Yang W; Wang H; Wang S; Zhang ZY; Wu W; Chen MH; Yan K; Goldberg SN
Radiology; 2021 Aug; 300(2):458-469. PubMed ID: 34003058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]